Distinct Thresholds of Infliximab Trough Level Are Associated with Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease: A Prospective Observational Study.

Date publication

novembre 2017

Journal

Inflammatory bowel diseases

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Roblin X, Boschetti G, Duru G, Williet N, Deltedesco E, Phelip JM, Peyrin-Biroulet L, Nancey S, Flourié B, Paul S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28945636

Résumé

Several studies have reported a strong correlation between infliximab (IFX) trough levels (trough levels of infliximab [TLI]) and clinical remission (CR). We aimed to determine threshold values of TLI associated with the occurrence of CR, with or without normal inflammatory biomarkers, including serum C-reactive protein (CRP) and fecal calprotectin (fCal).

Mots clés

Adolescent, Adult, Biomarkers, analysis, C-Reactive Protein, analysis, Drug Monitoring, Feces, chemistry, Female, France, Gastrointestinal Agents, administration & dosage, Humans, Inflammatory Bowel Diseases, drug therapy, Infliximab, administration & dosage, Leukocyte L1 Antigen Complex, analysis, Logistic Models, Male, Middle Aged, Prospective Studies, ROC Curve, Remission Induction, Severity of Illness Index, Tertiary Care Centers, Young Adult

Référence

Inflamm. Bowel Dis.. 2017 11;23(11):2048-2053